Hematology-OncologyCAR T-cell therapyCiltacabtagene autoleucel
Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry
By MedXY|Oct 14, 2025
A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the
